California voters face a closely contested November 3, 2026 decision on Proposition 38, an $8.4 billion general obligation bond for immunology and immunotherapy research. Trader sentiment reflects a near-even split between support for allocating half the proceeds to a University of California-affiliated institute and the remainder to competitive grants at public and nonprofit institutions—with at least half directed toward cancer, heart disease, and Alzheimer’s—and opposition centered on the estimated $500–600 million annual General Fund repayment cost over roughly 20 years. The measure includes price discounts for California patients and revenue-sharing requirements intended to offset debt, yet concerns about state borrowing amid broader budget pressures keep the outcome balanced. Endorsements from disease advocacy groups and the Democratic Party contrast with critiques from fiscal watchdogs, while developments such as campaign spending, updated economic forecasts, or shifts in federal research funding could alter the narrow implied probability before election day.